

Innovation all for the patients



Roche A member of the Roche group

## Roche Presents Data at American Society of Hematology (ASH) Annual Meeting

TOKYO, December 12, 2022 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that Roche issued a press release on data presentation regarding therapeutic antibodies created by Chugai, Hemlibra<sup>®</sup> and crovalimab, at the American Society of Hematology (ASH) Annual Meeting.

Please refer to the link below for details:

- Interim data from phase III study presented at ASH 2022 show Hemlibra achieved meaningful bleed control in infants from birth  
<https://www.roche.com/media/releases/med-cor-2022-12-11b>
- Roche's subcutaneous crovalimab given every four weeks achieves disease control in people with PNH, a life-threatening blood condition  
<https://www.roche.com/media/releases/med-cor-2022-12-11>

Trademarks used or mentioned in this release are protected by laws.

###